Featured Research

from universities, journals, and other organizations

Risk Factors For Blood Clots, Venous Thromboembolism, In Women Identified

Date:
January 13, 2008
Source:
University of Vermont
Summary:
Preliminary data from two Women's Health Initiative trials that assessed factors that indicate increased risk of venous thromboembolism (VTE) with postmenopausal hormone therapy is now available. VTE refers to a blood clot that forms in the veins, usually in the legs. These clots can become fatal if they travel through the veins to the lung. According to the American Heart Association, more than 200,000 cases of VTE occur each year and 30 percent of these people die within three days. It is known that postmenopausal hormone treatments can double the risk of developing VTE, and in recent years hormone prescriptions have declined, partly as a result of this.

University of Vermont cardiovascular physician-scientists Mary Cushman, M.D., and Matthew Watkins, M.D., are conducting cutting-edge research on the number-one killer of men and women in the United States -- cardiovascular disease.

Related Articles


Hormones and blood clot risk

In early December 2007, Cushman presented preliminary data from two Women’s Health Initiative trials that assessed factors that indicate increased risk of venous thromboembolism (VTE) with postmenopausal hormone therapy. VTE refers to a blood clot that forms in the veins, usually in the legs. These clots can become fatal if they travel through the veins to the lung. According to the American Heart Association, more than 200,000 cases of VTE occur each year and 30 percent of these people die within three days. It is known that postmenopausal hormone treatments can double the risk of developing VTE, and in recent years hormone prescriptions have declined, partly as a result of this.

“If these findings are confirmed, measurement of some of these factors might assist women with decision-making about whether or not to take estrogen or estrogen plus progestin for treatment of postmenopausal symptoms," said Cushman. "This becomes very important since hormones remain a very effective treatment for menopausal symptoms."

Women with angina better candidates for angiogenic therapy

A reported 8.9 million people in the United States, including 4.6 million women, live with chronic angina, the debilitating chest pain, squeezing or pressure experienced by people with coronary heart disease. However, women with heart disease have been largely underrepresented in cardiovascular clinical trials. A recent study article co-authored by Matthew Watkins, M.D., professor of medicine at the University of Vermont College of Medicine, indicates that an experimental treatment designed to promote blood vessel growth and improve cardiovascular blood flow in patients with angina may have a positive treatment effect in women as opposed to men.

The AGENT (Angiogenic Gene Therapy) studies (1 through 4) have to date involved 663 patients at more than one hundred U.S., European and other international medical centers. The experimental therapy under examination in the AGENT trials is Generx™ (alferminogene tadenovec, Ad5FGF-4), a gene product in a new class of cardiovascular biologics that when administered by intracoronary injection, promotes angiogenesis – the process of blood vessel growth in the heart. For their September 11, 2006 Journal of American College of Cardiology article, Watkins and his colleagues analyzed pooled original data from the AGENT -3 and -4 trials to determine treatment effects in two subgroups, gender and older patients with severe angina.

The study used exercise tolerance testing time to track any changes from baseline at 4 weeks, 12 weeks and 6 months among three groups – placebo, low-dose Ad5FGF-4 and high-dose Ad5FGF-4. At 12 weeks, there was significant improvement in women at both doses, but not in men.

Based on these findings, a Phase 3 clinical trial titled AWARE (Angiogenesis in Women with Angina pectoris who are not candidates for Revascularization) was launched in August 2007. UVM is one of more than two dozen centers in the country currently participating in this trial, which aims to enroll approximately 300 women with chronic angina who are not candidates for conventional bypass surgery or angioplasty in order to more closely examine the effects of angiogenic therapy on this population of patients.


Story Source:

The above story is based on materials provided by University of Vermont. Note: Materials may be edited for content and length.


Cite This Page:

University of Vermont. "Risk Factors For Blood Clots, Venous Thromboembolism, In Women Identified." ScienceDaily. ScienceDaily, 13 January 2008. <www.sciencedaily.com/releases/2008/01/080111200419.htm>.
University of Vermont. (2008, January 13). Risk Factors For Blood Clots, Venous Thromboembolism, In Women Identified. ScienceDaily. Retrieved November 29, 2014 from www.sciencedaily.com/releases/2008/01/080111200419.htm
University of Vermont. "Risk Factors For Blood Clots, Venous Thromboembolism, In Women Identified." ScienceDaily. www.sciencedaily.com/releases/2008/01/080111200419.htm (accessed November 29, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Saturday, November 29, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Rural India's Low-Cost Sanitary Pad Revolution

Rural India's Low-Cost Sanitary Pad Revolution

AFP (Nov. 28, 2014) — One man hopes his invention -– a machine that produces cheap sanitary pads –- will help empower Indian women. Duration: 01:51 Video provided by AFP
Powered by NewsLook.com
Research on Bats Could Help Develop Drugs Against Ebola

Research on Bats Could Help Develop Drugs Against Ebola

AFP (Nov. 28, 2014) — In Africa's only biosafety level 4 laboratory, scientists have been carrying out experiments on bats to understand how virus like Ebola are being transmitted, and how some of them resist to it. Duration: 01:18 Video provided by AFP
Powered by NewsLook.com
WHO Says Male Ebola Survivors Should Abstain From Sex

WHO Says Male Ebola Survivors Should Abstain From Sex

Newsy (Nov. 28, 2014) — WHO cites four studies that say Ebola can still be detected in semen up to 82 days after the onset of symptoms. Video provided by Newsy
Powered by NewsLook.com
Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins